Krystal®

Fourth Quarter and Full Year 2023 Financial Results and Business Update

February 26, 2024

Forward Looking Statements and Disclosures

Forward Looking Statements

This presentation contains forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about future expectations, plans and prospects for Krystal Biotech, Inc. (together with or its subsidiaries and affiliates, the "Company"), including but not limited to statements about the Company's U.S. commercial launch of VYJUVEK®; the Company's efforts to bring B-VEC to market in Europe, Japan, and elsewhere, and the expected timing of marketing approvals; the market opportunity for VYJUVEK; the Company's technology platform; the development and commercialization of the Company's product candidates, including conduct and timelines of clinical trials and regulatory filings; estimated financial measures, including 2024 non-GAAP combined R&D and SG&A expense guidance; and other statements containing the words "anticipate", "believe", "estimate", "expect", "intend", "may", "plan", "predict", "project", "target", "potential", "likely", "will", "would", "could", "should", "continue" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the content and timing of decisions made by regulatory authorities; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of early clinical trials or studies in different disease indications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; the availability or commercial potential of product candidates; the sufficiency of cash resources; and such other important factors as are set forth in the Company's annual and quarterly reports and other filings on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this presentation represent the Company's views as of the date of this presentation. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this presentation.

This presentation and the accompanying oral presentation include non-GAAP combined R&D and SG&A expense guidance, a supplemental measure of the Company's performance that is not required by, or presented in accordance with, U.S. GAAP and should not be considered as an alternative to R&D and SG&A expense or any other performance measure derived in accordance with GAAP. The Company defines non-GAAP combined R&D and SG&A expense as GAAP combined R&D and SG&A expense excluding stock-based compensation. The Company cautions investors that amounts presented in accordance with its definition of non-GAAP combined R&D and SG&A expense may not be comparable to similar measures disclosed by competitors because not all companies calculate this non-GAAP financial measure in the same manner. The Company has not provided a quantitative reconciliation of forecasted non-GAAP combined R&D and SG&A expense to forecasted GAAP combined R&D and SG&A expense because the Company is unable, without making unreasonable efforts, to calculate the reconciling item, stock-based compensation expenses, with confidence. This item, which could materially affect the computation of forward-looking GAAP combined R&D and SG&A expense, is inherently.

This presentation and the oral presentation may also contain estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other data. This data involves a number of assumptions and limitations, and investors are cautioned not to give undue weight to such estimates. Neither the Company nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, projections, assumptions and estimates of the Company's future performance and the future performance of the markets in which the Company operates are necessarily subject to a high degree of uncertainty and risk.

Other than VYJUVEK, all products described in this presentation are investigational therapies.

2023 Was a Breakthrough Year for Krystal

- Received FDA approval for VYJUVEK®, the first and only corrective therapy for DEB
- Strong U.S. launch underway with $50.7M in net product revenue in only two quarters since approval
- Significant progress and expansion of clinical pipeline with 5 active clinical trials planned in 2024
- Strong Balance Sheet with $594.1M in cash and investments
- Our 2 CGMP facilities support ambitious 2024 growth plans

Over $50M in Product Net Revenue in First 6 Months Post Approval



- Gross margins of 93% in Q4
- Gross-to-net adjustments in Q4 were 14%
- Transient impact from J-code | Price cap accruals

Significant Revenue Growth Opportunities Outside of the United States

$1B+ Global VYJUVEK Market Opportunity



* Refers to EU target markets of EU-4 (France, Germany, Spain, Italy), UK, Ireland, Benelux, Switzerland, Austria, Nordics

Expanding and Repeat Prescriber Supports Continued Patient Penetration

Rapid Penetration of U.S. Patient Pool



Start Forms Split By DEB Subtype



Start Form Split By HCP Setting



Over 195 unique prescribers to date, of which 60 are repeat prescribers

Prescribing metrics as of February 2024

Successfully Securing Broad Access and Reimbursement for VYJUVEK

228 Reimbursement Approvals To Date for VYJUVEK Patients



Positive Coverage for Over 93% of Commercial and Medicaid Covered Lives

Commercial Covered Lives

Estimated 169M on Commercial Plans in U.S.*



97%
Positive Access

Medicaid Covered Lives

Estimated 96M on Medicaid Plans in U.S.**



88%
Positive Access

Metrics as of February 2024

High Demand for Home Dosing and Strong Patient Compliance

VYJUVEK Site of Care (February 2024)



Patient Compliance (2023)

96%

Key Dynamics of VYJUVEK Launch

- COE patient visits are complex and occurring at a steady pace
- Many prior COE DEB patients are now actively managed in the community
- Logistical aspects of scheduling an HCP and integrating into existing wound care routines

VYJUVEK is Changing the Treatment Paradigm in DEB

Validating the Breadth of Krystal's Redosable Gene Therapy Platform

		Indication	Payload	Preclinical	Phase 1/2	Phase 3	Commercial
Vyjuvek® beremagene geperpavec-svdt 5x10⁹ PFU/mL single-use vial		Dystrophic epidermolysis bullosa (DEB)	*COL7A1*	**FDA Approved May 2023**			Marketed in the U.S.
Dermatology	**KB105**	Autosomal recessive congenital ichthyosis (ARCI)	*TGM1*				
	KB104	Netherton syndrome	*SPINK5*				
	Additional program(s) targeting dermatology indications						
Respiratory	**KB407**	Cystic fibrosis	*CFTR*				
	KB408	Alpha-1 antitrypsin deficiency (AATD)	*SERPINA1*				
	Additional program(s) targeting respiratory indications						
Oncology	**Injectable KB707**	Solid tumors including cutaneous	*IL2 + IL12*				
	Inhaled KB707	Solid tumors of the lung	*IL2 + IL12*				
Ophthalmology	**Ophthalmic B-VEC**	Ocular complications of DEB	*COL7A1*				
	Program(s) targeting ophthalmology indications						

B-VEC, beremagene geperpavec; CFTR, cystic fibrosis transmembrane conductance regulator; COL7A1, collagen type VII alpha 1 chain; IL12, interleukin-12; IL2, interleukin-2; SERPINA1, serpin family A member 1; SPINK5, serine protease inhibitor Kazal-type 5; TGM1, transglutaminase-1

With FDA Approval of VYJUVEK, Development Focus Now on Ex-U.S. Markets

Europe

- Marketing authorization application validated in November 2023
- On track for 2H 2024 decision



Japan

- Received Orphan Drug Designation from PMDA in December 2023
- Fully enrolled bridging trial and on track to file in 2H 2024
- Decision expected in 2025

5 Clinical Trials in 2024

Ophthalmology

- First clinical data on B-VEC eyedrops published in the *New England Journal of Medicine*
- Observed full corneal healing and visual acuity improvement from hand motion to 20/25
- Aligned with FDA on single arm, open label trial to support registration and expect to start study in 2H 2024

Respiratory

1

- Initiated dosing in Cohort 2 of KB407 Phase 1 trial CORAL-1
- No severe or serious adverse events in Cohort 1 of CORAL-1
- Cleared IND and dosed first patient in KB408 Phase 1 trial SERPENTINE-1

2

Oncology

3

- Dosed first patient with intratumoral KB707 in Phase 1 trial OPAL-1
- Cleared IND to evaluate inhaled KB707 in Phase 1 trial KYANITE-1
- Received Fast Track Designation for inhaled KB707
- Expect to start dosing KYANITE-1 before end of 1H 2024

4

JEUNE

- Initiated dosing in Phase 1 Cohort 4 evaluating KB301 in décolleté region
- Expecting data readouts from both Cohort 3 and Cohort 4 of the Phase 1 study in 2024

5

Fourth Quarter and Full Year 2023 Financial Highlights

Cash and investments: $594.1M as of December 31, 2023

($ in millions)	Three months ended December 31, 2023	Three months ended December 31, 2022	Year ended December 31, 2023	Year ended December 31, 2022
Product revenue, net	$42.1M	-	$50.7M	-
Cost of goods sold	$2.9M	-	$3.1M	-
R&D expenses	$11.4M	$10.7M	$46.4M	$42.5M
SG&A expenses	$24.8M	$24.0M	$98.4M	$77.7M
Stock-based compensation expense	$9.9M	$9.6M	$39.9M	$33.2M

Non-GAAP R&D and SG&A Expense Guidance for Full Year 2024:*

- **$150M to $175M***
- Excluding stock-based compensation

GAAP, generally accepted accounting principles; R&D, research and development; SG&A, selling, general, and administrative expenses

*Non-GAAP combined R&D and SG&A Expense guidance does not include stock-based compensation as we are currently unable to confidently estimate Full Year 2024 stock-based compensation expense. As such, we have not provided a reconciliation from forecasted non-GAAP to forecasted GAAP combined R&D and SG&A Expense in the above. This could materially affect the calculation of forward-looking GAAP combined R&D and SG&A Expenses, as it is inherently uncertain.

Developing Genetic Medicines for Rare Diseases